Analytics 4 Life, a life science startup utilizing artificial intelligence and machine learning in the fight against heart diseases which operates in RTP and Canada, will continue its battle with $25 million in new funding.
The company anticipates approval by the FDA and the making available of its proprietary imaging technology called CorVista in 2018.
CorVista diagnoses heart disease noninvasively through a series of sensors linked via the cloud for analysis by the firm’s diagnosing algorithm. A clinical trial is currently underway in the U.S. with more than 2,000 patients enrolled across 13 sites. Preliminary results will be disclosed at an upcoming conference, according to the company.
The system seeks to diagnose “coronary artery disease (CAD) using intrinsic signals scanned from the body without radiation, contrast agents, or cardiac stress,” the company notes.
- VIDEO: Watch an overview at https://vimeo.com/172252750
“Heart disease is the leading cause of death globally, with 1 in 7 deaths in the U.S. attributed to CAD. We are thankful for the continued support from passionate investors who have made it possible for us to revolutionize the way that CAD is diagnosed,” said Don Crawford, the firm’s CEO, in announcing the funding.
“Securing this oversubscribed financing fuels our rapid growth to advance development of our diagnostic tool and gives us the resources we need to deliver this game-changing technology to patients and physicians.”
A group of investors, including physicians and healthcare professionals, provided the Series B funding.
